NMNH vs NMN: What Is the Difference, and Is NMNH Better?

Disclosure: Nadosei wrote this guide, and Nadosei sells an NMN supplement. This page compares two NAD+ precursors. It does not review any product, and it is not medical advice. Each study below has a link, so you can check it.

NMNH is a newer name on NAD+ supplement labels, and some sellers call it a stronger NMN. In lab studies, it did raise NAD+ more than NMN. The human data is new: the only human trial that we found published its results in August 2026.

This guide explains what NMNH is, how it differs from NMN, and what the studies in cells, mice and people show. We checked every study on 13 October 2026.

The quick answer

• NMNH is the reduced form of NMN. The same change turns NAD+ into NADH.
• In cells and mice, NMNH raised NAD+ more and faster than NMN [1] [2]. It also changed more cell processes than NMN [3].
• In people, one 90-day trial in 80 healthy adults found NMNH well tolerated, and blood NAD+ rose with the dose. The results are a preprint: other scientists have not reviewed them yet [4].
• NMN has more human trials [5] [6]. We found no trial that compares NMNH and NMN directly in people.

NMNH vs NMN at a glance

	NMN	NMNH
Full name	Nicotinamide mononucleotide	Reduced nicotinamide mononucleotide
Form	Oxidized, like NAD+	Reduced, like NADH
Route to NAD+	Enzymes called NMNATs turn it into NAD+ [3]	A different route that depends on the enzyme adenosine kinase. It raises NADH too [3]
NAD+ rise in cells	Smaller	Larger and faster [1] [3]
Other effects in lab studies	Fewer changes in liver cells [3]	Broader changes in metabolism and gene activity [3]. Slowed cell growth in cell culture [2]
Human trials	Yes, in healthy adults: 250 mg a day for 12 weeks [6], and 300 to 900 mg a day for 60 days [5]	One that we found, in healthy adults: 125 to 500 mg a day for 90 days, a preprint [4]
Safety in people	Well tolerated up to 900 mg a day for 60 days [5]	Well tolerated up to 500 mg a day for 90 days [4]

What is NMNH?

NMNH is short for reduced nicotinamide mononucleotide. It is NMN in its reduced form, which means that it holds extra electrons. The same change turns NAD+ into NADH, and our guide to NAD+ vs NADH explains it step by step.

In 2021, two lab studies reported that NMNH raises NAD+ in cells and mice [1] [2]. In early 2026, the authors of a third lab study wrote that NMNH remained untested in humans [3]. In August 2026, the results of a human trial came out as a preprint [4].

How your cells use NMN and NMNH

Both are NAD+ precursors: your cells turn them into NAD+. They take different routes.

• NMN: enzymes called NMNATs turn NMN into NAD+ [3].
• NMNH: cells use a different route that depends on the enzyme adenosine kinase [3]. In mouse liver cells, NMNH raised NADH as well as NAD+, and NMN did not raise NADH [3].

In the same cells, the ratio of NAD+ to NADH rose only a little with each precursor, and by a similar amount [3].

Is NMNH better than NMN?

For one measure, the NAD+ level, the lab data favors NMNH:

• In cells, NMNH raised NAD+ much more and faster than NMN or NR [1]. A 2026 study in mouse liver cells found the same [3].
• In mice that received NMNH, NAD+ in the blood rose fast and stayed high. NAD+ also went up in the liver, kidney, muscle, brain, brown fat and heart, but not in white fat [1].
• A second research group found NMNH a better NAD+ booster than NMN in cells and in mice [2].

Claims that NMNH is many times stronger than NMN come from these studies in cells and mice. We found no study in people that compares the two.

A bigger NAD+ rise is not the full picture. The same lab studies found effects that NMN did not show:

• In cell culture, NMNH slowed glycolysis and the citric acid cycle, two main energy pathways, and it slowed cell growth. In mice, it caused no visible change in body weight [2].
• In mouse liver cells, NMNH and NRH, the reduced form of NR, changed metabolism and gene activity much more than NMN and NR. Stress-related genes called glutathione S-transferases went up, but glutathione itself did not fall. The authors call the reduced precursors distinct from the NMN and NR on the market [3].

What these lab effects mean for people is not known. On 13 October 2026, we searched Europe PMC and ClinicalTrials.gov for a human trial that compares NMNH and NMN directly, and we found none.

What the human trial of NMNH shows

It was a randomized, double-blind, placebo-controlled trial with 80 healthy adults aged 40 to 65. They took a placebo or a calcium salt of NMNH (NMNH-Ca) at 125, 250 or 500 mg a day for 90 days [4]. The trial registry lists the company EffePharm as the sponsor, and the tested product is UthPeak NMNH. The trial ran at two hospitals in India [7].

• Safety: NMNH was well tolerated at all 3 doses. The trial reported no serious adverse events, no adverse events from the treatment, and no participant stopped [4].
• After one dose: blood NAD+ rose and was highest at about 12 hours [4].
• After 90 days: blood NAD+ rose with the dose. The average rise from the start was 2.33 µM with placebo, and 8.22, 15.85 and 39.90 µM with 125, 250 and 500 mg [4].
• Other measures: the trial also measured a blood-based age estimate, a walk test and quality of life. The authors call these results exploratory [4].

Keep the limits in mind. It is one trial, with 80 people, over 90 days. It is a preprint, so other scientists have not reviewed it yet. A company sponsored it [7]. Two NMN companies also paid for the 60-day NMN trial below [5].

What the human trials of NMN show

• In a 60-day randomized trial, 80 healthy middle-aged adults took a placebo or 300, 600 or 900 mg of NMN a day. Blood NAD+ rose in all NMN groups at day 30 and day 60, and it was highest with 600 and 900 mg. The authors found no safety issues [5].
• In a 12-week trial, 250 mg of NMN a day raised blood NAD+ and caused no abnormal findings [6].

The 60-day NMN trial and the NMNH trial have a similar design. But they are separate trials, with different products and different lengths, so their NAD+ numbers do not compare directly. Our complete NMN guide covers more NMN trials.

How much NMNH do people take?

The only human trial that we found tested 125, 250 and 500 mg a day for 90 days [4]. These are trial doses, not a recommendation. The NMN trials above used 250 to 900 mg a day [5] [6], and our NMN dosage guide covers NMN doses in detail.

Side effects and safety

• NMNH: well tolerated at 125 to 500 mg a day for 90 days, with no serious adverse events [4]. We found no human data for longer than 90 days.
• NMN: no safety issues at up to 900 mg a day for 60 days [5], and no abnormal findings at 250 mg a day for 12 weeks [6].
• For everyone: talk to your doctor before you start either one if you are pregnant or breastfeeding, have a medical condition, or take medicines.

NMNH vs NAD+

NAD+ is the end product. NMNH and NMN are precursors: your cells turn them into NAD+. Our NMN vs NAD+ comparison explains the difference between a precursor and NAD+ itself, and our NAD+ supplements guide covers the full topic.

The bottom line

NMNH is the reduced form of NMN. In cells and mice, it raised NAD+ more and faster than NMN, and it also changed more cell processes. In people, one 90-day trial found it well tolerated, and blood NAD+ rose with the dose; the results are a preprint. NMN has more human trials, and we found no trial that compares the two directly in people. If you consider NMNH, know that its human data is one early trial, and ask your doctor which option fits you.